Premium
In vitro effects of the chemotherapy agent water‐soluble micellar paclitaxel (Paccal Vet) on canine hemangiosarcoma cell lines
Author(s) -
Reckelhoff Caroline R.,
Lejeune Amandine,
Thompson Patrick M.,
Shiomitsu Keijiro
Publication year - 2019
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12442
Subject(s) - paclitaxel , apoptosis , hemangiosarcoma , cell culture , cell cycle , basic fibroblast growth factor , vascular endothelial growth factor , cell growth , flow cytometry , chemistry , in vitro , annexin , pharmacology , cell , cell cycle checkpoint , microbiology and biotechnology , growth factor , biology , chemotherapy , medicine , cancer research , biochemistry , vegf receptors , pathology , receptor , angiosarcoma , genetics
Paccal Vet (Osamia Pharmaceuticals) is a water‐soluble nanoparticle micellar formulation of the drug paclitaxel that is well tolerated in dogs. This study evaluated the in vitro effect of Paccal Vet on two canine hemangiosarcoma (HSA) cell lines and their expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Paccal Vet caused HSA cell death in a dose‐ and time‐dependent manner. The 50% inhibitory concentration (IC 50 ) for the two HSA cell lines were 7 to 610 ng/mL, which are clinically achievable. Cell cycle analysis through flow cytometry showed cell cycle arrest at G2/M phase. Annexin‐V and caspase 3/7 activity assays showed significant increases in apoptosis in correlation with the IC 50 in each cell line. Reverse transcriptase‐PCR was performed on the cell lines to validate the gene expression of VEGF and bFGF. Results obtained from this study support future studies involving the use of paclitaxel (micellar) for treatment of canine HSA.